Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy

Documents similaires

• A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
  par: Myrl Holida, et autres
  Publié: (2024)
• Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapy
  par: Christoph Kampmann, et autres
  Publié: (2024)
• Long‐term cardiovascular outcomes and mortality with enzyme replacement therapy in patients with mucopolysaccharidosis type II
  par: Ji Hee Kwak, et autres
  Publié: (2024)
• Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency
  par: Henry H. C. Lee, et autres
  Publié: (2024)
• Use of pure recombinant human enzymes to assess the disease‐causing potential of missense mutations in urea cycle disorders, applied to N‐acetylglutamate synthase deficiency
  par: Nadine Gougeard, et autres
  Publié: (2024)